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Abstract
Heart failure (HF) continues to be a serious public health challenge despite significant advancements in therapeutics and 
is often complicated by multiple other comorbidities. Of particular concern is type 2 diabetes mellitus (T2DM) which not 
only amplifies the risk, but also limits the treatment options available to patients. The sodium-glucose linked cotransporter 
subtype 2 (SGLT2)-inhibitor class, which was initially developed as a treatment for T2DM, has shown great promise in 
reducing cardiovascular risk, particularly around HF outcomes – regardless of diabetes status.
There are ongoing efforts to elucidate the true mechanism of action of this novel drug class. Its primary mechanism of induc-
ing glycosuria and diuresis from receptor blockade in the renal nephron seems unlikely to be responsible for the rapid and 
striking benefits seen in clinical trials. Early mechanistic work around conventional therapeutic targets seem to be inconclu-
sive. There are some emerging theories around its effect on myocardial energetics and calcium balance as well as on renal 
physiology. In this review, we discuss some of the cutting-edge hypotheses and concepts currently being explored around 
this drug class in an attempt better understand the molecular mechanics of this novel agent.
Keywords SGLT2-inhibitors · Renal disease · Heart failure · Calcium handling · Myocardial energetics · Ventricular 
remodelling
Introduction
Heart failure (HF) is a growing public health concern with 
8.5 million people expected to be living with this condition in 
the year 2030 at a staggering cost of $70 billion in the United 
States alone [1]. HF not only shortens life, but also reduces 
its quality. There have been considerable advancements in the 
management of this disease using a variety of neurohormonal 
modulators and, more recently, with device therapy. Never-
theless, HF remains a challenge to treat particularly because 
it is frequently associated with other co-morbidities such as 
hypertension, type 2 diabetes mellitus (T2DM), ischaemic 
heart disease and renal impairment. Ischaemic heart disease 
is the commonest cause of heart failure and T2DM ampli-
fies that risk further. Patients with ischaemic cardiomyopathy 
and T2DM face a doubling of mortality risk compared to 
patients without T2DM. Indeed, T2DM increases mortality 
risk regardless of the underlying aetiology of heart failure [2].
Interestingly, there appears to be a bidirectional relation-
ship between T2DM and HF; not only can T2DM cause HF, 
but it can also be the consequence of it [3]. This underscores 
the importance of optimal diabetes control in patients with 
HF. Although there is a multitude of efficacious medications 
for T2DM, they do not appear to reduce the risk of cardio-
vascular (CV) outcomes and in the context of HF—some of 
these agents may even be harmful. A meta-analysis involv-
ing 95,000 individuals showed a 42% increased risk of inci-
dent HF with the use of thiazolidinediones in patients with 
T2DM while DPPIV-inhibitors increased that risk by 25% [4]. 
Another meta-analysis of large HF trials showed patients with 
HF using insulin had a 27% increased risk of all-cause mor-
tality [5]. These data highlight the complexity, and potential 
dangers, of managing T2DM and HF concomitantly.
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A novel class of anti-diabetes therapy known as the 
sodium glucose-linked cotransporter subtype 2 (SGLT2) 
inhibitor has shown potential in addressing this area of 
urgent unmet need, not only by improving glycaemia but also 
preserving renal function and reducing hard HF outcomes 
as well. In this review, we discuss the evidence behind the 
striking CV benefits and unpick some of the unique charac-
teristics of this drug class that could potentially herald a new 
generation of targeted agents in the treatment of HF.
SGLT2 inhibitors – what it says on the tin
Canagliflozin, dapagliflozin, empagliflozin and ertugliflo-
zin are four currently available agents of the SGLT2-inhib-
itor class. All four are indicated for T2DM, while dapa-
gliflozin recently received FDA approval for HF, with or 
without T2DM [6]. As the name implies, SGLT2-inhibitors 
work by inhibiting the sodium-glucose cotransporter sub-
type-2, located in the S1 and S2 segments of the proximal 
convoluted tubule (PCT) of the kidney. SGLT2 is a low 
affinity high capacity transporter  (Km 2 mM) responsible 
for approximately 90% reabsorption of filtered plasma 
glucose, and the remainder is reabsorbed by SGLT1 [7]. 
Potent SGLT2-inhibition prevents the reabsorption of 
filtered glucose as well as sodium, resulting in glucosu-
ria and natriuresis. (Fig. 1) Other pleotropic benefits of 
SGLT2-inhibition include weight loss (1.8 to 2.7  kg), 
reductions in blood pressure (systolic blood pressure (BP): 
1.0–2.6 mmHg; diastolic BP 0.7–2.2 mmHg) [9], without 
increases in heart rate and a low potential of inducing 
hypoglycaemia [10].
Unlike other antidiabetic agents, the glucose lowering 
effect of SGLT2 inhibitors is independent of pancreatic 
beta-cell function and insulin sensitivity – an ideal property 
in the context of T2DM disease progression [11] and meta-
bolic milieu of the T2DM phenotype [12]. This insulin-
independent fall in plasma glucose reduces insulin require-
ments and induces a rise in the glucagon-to-insulin ratio, 
shifting metabolism towards a catabolic state [13]. The 
caloric loss coupled with increased lipolysis (from catabo-
lism) are responsible for the sustained steady-state weight 
loss seen with SGLT2-inhibition. (Fig. 2) Body composi-
tion studies have shown approximately two-thirds of sus-
tained weight loss is attributable to loss of body fat [14].
Fig. 1  Normal renal tubular resorption of glucose. The diagram also identifies the site at which SGLT2-inhibitors act [8]. Abbreviations: PCT-
proximal convoluted tubules; SGLT-sodium-glucose cotransporter
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In addition, glucosuria and natriuresis simulate an 
osmotic diuretic effect resulting in reduced plasma vol-
ume. Filtered glucose that is not reabsorbed increases 
tubular fluid osmolarity, flattening the osmotic gradient 
between tubular fluid and the interstitium thereby reduc-
ing electrolyte-free water reabsorption. This is expected 
to provide some relief on cardiac filling volume and 
blood pressure which in turn results in reduced preload 
and afterload respectively. (Fig. 2) Unlike conventional 
sodium-driven diuretics, SGLT2-inhibititor-mediated 
free water excretion is expected to be more efficient in 
relieving signs and symptoms of interstitial congestion 
without adversely compromising intravascular fluid status 
or causing reflex sympathetic activation [15, 16]. The 
recently published RECEDE-CHF trial confirmed that in 
a cohort of patients with established HF on long-term 
diuretic therapy, the addition of empagliflozin increased 
urine output by over 500 ml/day and more than half of 
that volume was in the form of electrolyte-free water 
clearance [17].
These are the primary mechanisms of action of the 
SGLT2-inhibitor class that have been purported to be 
responsible for its beneficial effects, however as our 
understanding of this drug class evolves there is a recog-
nition that there may be other novel pathways at play – we 
explore these pathways in the later sections of this article.
Cardiovascular outcome trials – the breakthrough
In 2015, the Empagliflozin Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG 
OUTCOME) was the first FDA-mandated cardiovascular 
outcome trial (CVOT) of the class. It studied 7020 indi-
viduals with T2DM, randomised to empagliflozin or placebo 
over a mean follow-up period of 3.1 years [18]. There were 
striking reductions in 3-point major adverse cardiovascular 
events (MACE); (HR 0.86; 95% CI 0.74–0.99), all-cause 
mortality (HR 0.68; 95% CI 0.57–0.82), CV mortality (HR 
0.62; 95% CI 0.49–0.77) and HF hospitalisation (HR 0.65; 
95% CI 0.50–0.85) [18]. Further analyses revealed the CV 
benefit with empagliflozin was independent of CV comor-
bidity burden [19, 20] and renal function [21]. Although 
the most promising effects of the drug were around HF 
outcomes, only 10% of the cohort had a diagnosis of HF 
prior to randomisation and, importantly, there was no for-
mal confirmation / characterisation of HF (e.g. by measur-
ing natriuretic peptides or performing echocardiography). 
Another unexpected finding was the rapidity of benefit, with 
the HF hospitalisation and CV mortality curves diverging 
within weeks of initiation of therapy.
The Canagliflozin Cardiovascular Assessment Study 
(CANVAS) and Dapagliflozin Effect on Cardiovascu-
lar Events-Thrombolysis in Myocardial Infarction 58 
Fig. 2  Overview of the effects of SGLT2-inhibitor therapy. Abbre-
viations: CV-cardiovascular; EPO-erythropoietin; Hb-haemoglobin; 
Hct-haematocrit; NHE-1- sodium-hydrogen exchanger subtype-1; 
PCT-proximal convoluted tubule (of renal nephron); SGLT-sodium-
glucose linked cotransporter; TG-tubuloglomerular
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(DECLARE-TIMI 58) trials were the next two CVOTs 
to establish CV safety and efficacy of canagliflozin and 
dapagliflozin respectively. Both studies utilised a broader 
inclusion criteria of patients, which included those at high 
risk of developing CV disease as well as patients with 
already established CV disease. The majority of partici-
pants in CANVAS had established CV disease, while the 
reverse was true for DECLARE-TIMI 58. Both had a sim-
ilar proportion of patients with a history of HF to EMPA-
REG OUTCOME. Canagliflozin significantly reduced 
3-point MACE (HR 0.86; 95% CI 0.75–0.97) and HF 
hospitalisation (HR 0.67; 95% CI 0.52–0.87), but there 
was no significant reduction in mortality [22]. Dapagli-
flozin had no effect on 3-point MACE (HR 0.93; 95% CI 
0.84—1.03) or CV death (HR 0.98; 95% CI 0.82–1.17) 
but there was still significantly lower hospitalisations 
for HF (HR 0.73; 95% CI 0.61–0.88) [23]. In post-hoc 
analysis of DECLARE-TIMI 58 where participants were 
stratified by ejection fraction, dapagliflozin reduced risk 
of CV death and HF hospitalisation to a greater extent in 
patients with reduced ejection fraction (EF) [24], however 
these findings are to be interpreted with caution given 
the small proportion of patients and lack of robust char-
acterisation of HF. A meta-analysis of all three CVOTs 
showed an overall 14% reduction in MACE, 23% reduc-
tion in composite HF hospitalisation and CV death and 
45% reduction in renal disease progression [25]. These 
findings have also been reproduced in large, real-world 
clinical studies [26, 27].
Cardiovascular Outcomes Following Ertuglif lozin 
Treatment in Type 2 Diabetes Mellitus Participants With 
Vascular Disease (VERTIS CV) is the most recent CVOT 
to investigate effects of ertugliflozin in over 8000 patients 
with established CV disease [28]. The inclusion crite-
ria used was very similar to EMPA-REG OUTCOME, 
with a larger proportion of patients with HF at baseline 
in VERTIS CV (23.1% vs 10.1%). Ertugliflozin failed 
to demonstrate superiority in the primary outcome of 
3-point MACE (HR 0.97 95% CI 0.85–1.11) or any of 
the key secondary outcomes; CV death (HR 0.92 95% CI 
0.77–1.11) and renal disease progression (HR 0.81 95% 
CI 0.63—1.04). However, a 30% reduction in risk of hos-
pitalisation for HF was seen with ertugliflozin, consistent 
with the class effect seen in previous CVOTs. The dis-
cordant results in CV death or renal disease progression, 
especially in a secondary prevention cohort is surprising 
given the benefits seen in other CVOTs; further analysis 
is awaited.
Findings from these trails led the leading cardiac (and 
diabetes) societies to recommend the use of SGLT2-inhib-
itors in patients with coronary artery disease with T2DM 
to reduce the risk of future CV events [29, 30].
HF with reduced ejection fraction – SGLT2‑inhibitors 
are fast becoming a must have drug
The Dapagliflozin and Prevention of Adverse outcomes in 
Heart Failure (DAPA-HF) trial was the first to prospectively 
investigate the benefits of dapagliflozin in a HF population 
with reduced ejection fraction (HFrEF) with or without 
diabetes. Dapagliflozin demonstrated a remarkable reduc-
tion in composite CV death or worsening HF (defined as 
hospitalisation or urgent visit for HF) (HR 0.74 [95% CI 
0.65–0.85]), with each component being reduced by 18% 
and 30% respectively [31]. Patients also experienced less 
symptoms of HF in the dapagliflozin arm compared to 
conventional HF therapy as evidenced by a significant and 
clinically meaningful improvement in Kansas City Cardio-
myopathy Questionnaire score. Some noteworthy aspects 
of the study include: 1) majority of the participants were 
on well-established background HF therapy (ACEi/ARB/
ARNI 94%, BB 96%, MRA 71%), which further underscores 
the added, incremental benefit of dapagliflozin on CV out-
comes; 2) CV benefit manifested early and was maintained 
throughout course of the study; 3) short median follow-up 
period of 18 months as compared to other key HF therapies 
(with the exception of beta-blockers) and 4) pre-specified 
analyses showed CV benefit was consistent, regardless of 
diabetes status at baseline and there were no safety con-
cerns regarding hypoglycaemia or adverse volume depletion 
in non-diabetic HF patients [31].
Empagliflozin Outcome Trial in Patients with Chronic 
Heart Failure with Reduced Ejection Fraction (EMPEROR-
Reduced) was designed to be more ambitious than DAPA-
HF, recruiting a HF population that had on average more 
severe systolic dysfunction (mean EF 27% vs. 31%; N-ter-
minal pro B-type natriuretic peptide (NT-proBNP) 1907 vs. 
1437) [32]. After a median follow-up of 16 months, the inci-
dence of primary outcome of CV death or hospitalisation for 
HF was significantly reduced by empagliflozin therapy (HR 
0.75; 95% CI 0.65–0.86]), largely driven by lower HF hospi-
talisations. [32]. The lack of signal in CV mortality (HR 0.92; 
95% CI 0.75–1.12) was somewhat surprising. Perhaps, in 
patients with more advanced HF, the ability of empagliflozin 
to further reduce mortality risk may have been a step too far.
The true CV benefit with SGLT2-inhibition could be 
benchmarked against the only other novel therapy shown to 
reduce mortality in a well-treated HF population—the angi-
otensin receptor-neprilysin inhibitor sacubitril-valsartan, 
which works by augmenting the natriuretic peptide system 
and simultaneously inhibiting the renin–angiotensin–aldos-
terone system [33]. Dapagliflozin and empagliflozin both 
showed greater relative and absolute risk reduction in pri-
mary composite outcome of CV death or HF hospitalisation 
compared to sacubitril-valsartan (PARADIGM-HF) in com-
parable cohorts of HF patients [34]. The benefit seen with 
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SGLT2-inhibitors was primarily driven by superior reduc-
tions in HF hospitalisation. In fact, the effect size seen in the 
SGLT2-inhibitor trials may have been undermined by the 
relatively older and sicker (larger proportion of NYHA III/
IV) cohort and a significantly shorter median follow-up time.
HF with preserved ejection fraction – are 
SGLT2‑inhibitors the holy grail?
HF with preserved ejection fraction (HFpEF) makes up 
approximately half of the HF population. Both HFrEF and 
HFpEF have similar prognoses but very different patho-
physiology [35]. HFrEF is due to impaired emptying of the 
left ventricle (LV) from systolic dysfunction, perpetuated 
by systemic neurohormonal activation. HFpEF on the other 
hand is largely due to LV diastolic dysfunction, either pas-
sively from increased myocardial stiffness or actively from 
impaired relaxation [36]. The lack of efficacy seen with 
ACE-inhibitors/ARBs [37–39], MRAs [40] and sacubitril / 
valsartan [41] in HFpEF suggest that excessive loading is not 
a key pathogenic mechanism or adverse adaptation in this 
HF phenotype. Increasing evidence points to abnormalities 
at the cellular level (inflammation, myocardial energetics, 
calcium handling and extracellular matrix composition) 
as potential targets for HFpEF management [42]. As we 
will discuss in the subsequent sections, SGLT2-inhibitors 
have unique properties that could specifically address these 
molecular changes particularly around calcium handling and 
myocardial energetics.
Several large dedicated HFpEF studies; Empagliflo-
zin Outcome Trial in Patients with Chronic Heart Failure 
with Preserved Ejection Fraction (EMPEROR-Preserved) 
(NCT03057951) and Dapagliflozin Evaluation to Improve 
the Lives of Patients with Preserved Ejection Fraction Heart 
Failure (DELIVER) (NCT03619213), are nearing comple-
tion and will characterize SGLT2-inhibitor benefit in this 
cohort.
Cardiorenal syndrome – an unmet need in HF
The heart and kidney are inextricably linked, where direct 
or indirect effects of one dysfunctional organ can initiate 
and perpetuate the combined disorder of both organs, and 
is often referred to as the cardiorenal syndrome [43]. Up to 
60% of patients with HF have co-morbid chronic kidney dis-
ease (CKD), thus increasing their risk of mortality compared 
with patients with just HF alone [44, 45]. Besides cardio-
protection, the renal protective effects of SGLT2-inhibitors 
are derived from multiple converging pathways related to 
its primary mechanism of action; natriuresis and glucosuria.
In patients with T2DM, the increased filtered glucose 
elicits upregulation of SGLT1 and SGLT2 expression in 
the proximal convoluted tubule of the nephron. As a con-
sequence of the increased glucose (and sodium) absorption 
by these transporters in the proximal part of the nephron, 
there is reduced sodium delivery distally to the macula densa 
causing afferent renal arteriolar dilatation and hyperfiltra-
tion. Excessive hydrostatic damage to the glomerulus from 
hyperfiltration is thought to be the main driver for diabetic 
nephropathy [46]. By inhibiting sodium resorption in the 
proximal nephron thereby increasing distal delivery, SGLT2-
inhibitors can restore tubuloglomerular feedback and nor-
malise renal blood flow. The preferential effect of SGLT2-
inhibition on the afferent, rather than efferent arteriole, may 
explain why renal function returns to baseline after an ini-
tial dip in estimated glomerular filtration rate (eGFR), with 
stability over time (positive eGFR slope) [47, 48]. In com-
parison, RAAS-inhibitors slow renal disease progression but 
eGFR either stabilises after the initial dip or slowly declines 
over a similar period (negative eGFR slope) [49, 50]. In 
addition, cardiorenal syndrome severely limits the available 
options of HF medications (ACE-inhibitors/ARBs, MRAs 
and ARNIs), all of which cumulatively increase risk of acute 
kidney injury (AKI) and hyperkalaemia in a dose-depend-
ent manner. As Lam et al. point out, cardiorenal syndrome 
remains one of the key unmet needs in the management of 
HF, which could be directly addressed by SGLT2-inhibitors 
[51].
Following consistently positive effects on renal end-
points in early trials, the Evaluation of the Effects of 
Canagliflozin on Renal and Cardiovascular Outcomes in 
Participants with Diabetic Nephropathy (CREDENCE) 
trial was the first dedicated renal endpoint study in patients 
with diabetic kidney disease, using canagliflozin. Of the 
4401 patients, all had a diagnosis of chronic kidney dis-
ease, 50.4% also had established CV disease and 16% had 
baseline HF [52]. Canagliflozin delayed renal disease pro-
gression (HR 0.60; 95% CI 0.48–0.76) and reduced risk 
of end-stage kidney disease (HR 0.68; 95% CI 0.54–0.86) 
[52]. Risk of hospitalisation from HF was also signifi-
cantly reduced by 39%, consistent with results from previ-
ous CVOTs. There was no increase in incidence of AKI or 
hyperkalaemia with SGLT2 inhibition.
A Study to Evaluate the Effect of Dapagliflozin on 
Renal Outcomes and Cardiovascular Mortality in Patients 
With Chronic Kidney Disease (DAPA-CKD) provides fur-
ther affirmation for SGLT2-inhibitor use in both diabetic 
and non-diabetic CKD aetiologies. Dapagliflozin reduced 
the risk of worsening renal function or death from kidney 
failure by 44%, hospitalisation for HF or CV death by 29% 
and all-cause mortality by 31% (all p < 0.05) – regardless 
of T2DM status [53]. Results from EMPA-KIDNEY are 
keenly awaited.
 Heart Failure Reviews
1 3
Are SGLT2‑inhibitors a diabetes drug or a drug 
for HF and CKD?
Despite multiple guideline recommended disease-modifying 
therapies, patients with HF continue to have a poor progno-
sis [54]. Results from recent CV and renal outcome trials 
are very promising highlighting SGLT2-inhibitors’ poten-
tial to treat T2DM, CV disease, HF and CKD—conditions 
that are invariably linked by the common CV risk factor 
profile [18, 22, 23, 52]. It has also become evidently clear 
that the cardiorenal benefits of SGLT2-inhibitors are inde-
pendent of its modest reductions in conventional risk fac-
tors (HbA1c, blood pressure, cholesterol), T2DM status and 
renal function.
The question  remains: Should cardiologists and neph-
rologists be proactively prescribing SGLT2-inhibitors to all 
patients with CV and renal disease?
From a CV perspective, there have now been analyses 
of three patient groups; 1) primary prevention cohort (part 
of CANVAS and DECLARE TIMI-58), 2) secondary pre-
vention cohort (EMPA-REG OUTCOMES, VERTIS CV, 
part of CANVAS and DECLARE TIMI-58) and 3) HF 
cohort (DAPA-HF and EMPEROR-Reduced). As the CV 
risk profile increases, so does the apparent ‘efficacy’ of 
SGLT2-inhibition on CV mortality and HF hospitalisation. 
However, as seen in EMPEROR-Reduced, there is a signal 
that there may be an upper limit of HF severity beyond 
which the mortality benefits of SGLT2-inhibition pla-
teaus, whilst morbidity benefits (reduced hospitalisations) 
remain robust throughout the entire spectrum of disease 
risk and severity.
So far only canagliflozin has received regulatory approval 
for use in patients with T2DM and CKD following data from 
the CREDENCE trial [55]. In patients with non-diabetic 
nephropathy, the answer is slowly emerging, especially fol-
lowing very encouraging results from DAPA-CKD, resulting 
in it being granted fast-track designation by the FDA. [56]. 
This highlights the urgent clinical need to slow down CKD 
progression and improve quality of life as well as life expec-
tancy in this expanding cohort. Current evidence indicate 
that the renoprotective benefits conferred may just be the 
most striking effect of this drug class thus far—perhaps as a 
consequence of the very limited treatment options available 
for CKD, unlike in HF.
Mechanistic trials in SGLT2‑inhibitors—more 
questions than answers
A characteristic feature of the pathophysiology of HF is the 
activation of compensatory pathways; however, sustained 
activation of the neurohormonal system (sympathetic nerv-
ous system and renin–angiotensin–aldosterone system) 
results in maladaptive remodelling of the ventricles and 
myocardial injury, which perpetuate the disease state. Being 
able to reverse this remodelling is an important determinant 
of long-term severity of HF and mortality [57]. Previous HF 
therapies have all unequivocally exhibited reverse remodel-
ling effects on the failing heart [58–60]. It was therefore 
sensible that the main premise behind the first batch of 
mechanistic studies of SGLT2-inhibitors were based on the 
hypothesis that they too could induce reverse remodelling 
owing to the diuretic and BP lowering properties, which 
should improve ventricular loading in the dysfunctional 
ventricle.
The Research Into the Effect of SGLT2 Inhibition on Left 
Ventricular Remodeling in Patients With Heart Failure and 
Diabetes Mellitus (REFORM) trial was the first to try to deter-
mine the mechanistic effect of SGLT2-inhibitors specifically 
in the HF population. At 1 year, no significant difference in 
LV remodelling (LV end systolic volume, end diastolic vol-
ume, LV mass index or EF), as assessed by cardiac magnetic 
resonance imaging was seen with dapagliflozin therapy [61]. 
The absence of effect on remodelling was unexpected given 
the striking improvements in HF outcomes. There are two 
possible reasons why dapagliflozin therapy was neutral on LV 
remodelling. First, the majority of patients in the REFORM 
trial were on ACEi/ARBs (89%), beta-blockers (82%) and 
MRA (41%), which have potent effects on ventricular loading. 
The addition of an SGLT2-inhibitor, with only modest diuretic 
and BP effects, would thus confer little incremental benefit on 
haemodynamic load and parameters of LV remodelling. Simi-
lar conclusions can also be drawn from the DEFINE-HF Trial, 
where dapagliflozin did not significantly reduce NT-proBNP 
levels, a biomarker of ventricular end diastolic pressure, over 
12 weeks, as compared to placebo [62]. Second, improvement 
in LV remodelling seen with SGLT2-inhibitors appear to usu-
ally occur in the early stages of the disease spectrum. Post-hoc 
exploratory analyses from the REFORM trial suggest dapagli-
flozin reduced LV volumes and indexed LV mass in patients 
with LVEF ≥ 45%, with no interaction seen in other key sec-
ondary outcomes [63]. These findings are consistent with 
improvements in HF outcomes in the CVOTs, in which a large 
proportion of patients probably had early, occult HF. Other 
mechanistic trials such as the EMPA-HEART and DAPA-
LVH trials support this hypothesis, demonstrating reductions 
in LV mass in patients with T2DM and LV hypertrophy with-
out LV dysfunction or symptoms of HF [64].
Putting everything together, there is a definite clinical 
benefit from SGLT2-inhibitor therapy particularly in the 
context of hard HF outcomes, however the mechanism of 
that effect remains unclear (Table 1). The glucose-lowering 
and diuretic effects from its primary mode of action on the 
nephron, although important, simply cannot explain the 
speed and magnitude of benefit seen in the large outcome 
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trials. Early mechanistic trials on conventional markers of 
LV remodelling have been inconclusive, raising the possi-
bility that SGLT2-inhibitors act in a novel way that is not 
reflected by changes in LV remodelling as we currently 
understand them. In the following sections we explore 
new and emerging hypotheses into the molecular changes 
brought about by SGLT2-inhibition and their potential role 
in treating HF.
Calcium and the cardiomyocyte
The ionic balance within the cardiomyocyte is finely modu-
lated by a variety of ion pumps on the cell surface membrane 
which interact via multiple overlapping pathways. Calcium 
 (Ca2+), is a key ion involved in excitation–contraction cou-
pling, cardiac rhythmicity, also acting as a second messenger 
in regulating gene transcription for myocyte hypertrophy and 
other pathological remodelling pathways [71].
Action potentials generated at the cell surface trigger the 
opening of voltage-dependent L-type  Ca2+ channels facilitat-
ing Ca2+ influx into the cardiomyocyte where it then binds to 
ryanodine R2 receptors (RyR2) on the sarcoplasmic reticulm 
(SR) to release intrasarcoplasmic  Ca2+. This process (called 
calcium-induced calcium release) amplifies the cytoplasmic 
 Ca2+ content, which then bind to cardiac troponin, trigger-
ing muscle contraction. At the end of systole, the majority 
of  Ca2+ ions are recycled back to the SR for storage via the 
SR  Ca2+-ATPase (SERCA2a), while the rest are extruded 
extracellularly via the sodium-calcium exchanger (NCX) 
[72] (Fig. 3).
HF and T2DM cause structural and functional changes 
to these pumps, and in doing so, disrupt the finely-balanced 
calcium homeostasis. There is increased activity of phos-
pholamban which inhibits SERCA2a resulting in reduced 
 Ca2+ reuptake into SR. This prolongs the relaxation phase 
(causing diastolic dysfunction) and reduces SR  Ca2+ con-
tent available for use in the next contraction cycle (cauing 
systolic dysfunction). Likewise, phosphorylation of RyR2 
pumps cause diastolic leakage of  Ca2+ from the SR further 
reducing its storage capacity and increasing arrhythmogenic-
ity due to increased cytosolic  Ca2+ during diastole [73]. 
Additionally, there is also increased expression of SGLT1 
and the sodium-hydrogen exchanger 1 (NHE1) on the car-
diomyocyte cell membrane which increases intracytoplas-
mic sodium  (Na+) concentrations [74, 75]. This reduces the 
efficiency of NCX pumps on the cell surface as well as those 
on mitochondria (which require low intracytoplasmic  Na+ 
concentrations), resulting in increased cytoplasmic  Ca2+ and 
reduced mitochondrial  Ca2+ leading to myocyte hypertrophy, 
increased oxidative stress and accelerated cell death [76, 
77] (Fig. 3).
SGLT2 is not expressed on the heart [78], yet there 
is strong pre-clinical evidence that SGLT2-inhibitors Ta
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Fig. 3  Schematic representation of sodium and calcium ion balance in 
the cardiomyocyte. Figure 2a: Ion balance in a healthy heart. Figure 2b: 
Abnormal calcium and sodium balance as a consequence of heart fail-
ure and type 2 diabetes Abbreviations:  Ca2+-calcium;  K+-potassium; 
LTCa-L-type calcium channel;  Na+ -sodium;  Na+/K+ ATPase-sodium–
potassium adenosine triphosphatase pump; NCX-sodium-calcium 
exchanger; NHE-1-sodium-hydrogen exchanger subtype-1; PLB-phos-
pholamban; ROS-reactive oxygen species; RyR2-ryanodine receptor 2; 
SERCA2a- sarcoplasmic reticulum calcium adenosine triphosphatase 
subtype 2a; SGLT-1-sodium-glucose cotransporter subtype 1; Blue 
spheres: calcium ions; Orange cubes: sodium ions; Green sphere: glu-
cose molecule: Pink hexagon: potassium ion
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influence  Ca2+ handling by modulating intracytoplasmic 
 Na+ in the cardiomyocyte. This is supported by evidence 
that empagliflozin improves SERCA2a efficiency [79] and 
reduces RyR2-dependent  Ca2+ leak [80, 81]. Addition-
ally, empagliflozin may also preserve mitochondrial func-
tion and reduce oxidative damage [82]. SGLT2-inhibitors 
achieve this by inhibiting NHE1 (SGLT2-inhibitors inacti-
vate NHE1 by binding to its  Na+ binding site) and possibly 
SGLT1 as well (all SGLT2-inhibitors have intrinsic SGLT1 
blocking ability – albeit to different degrees) [77, 83, 84].
Interestingly, T2DM is not the only trigger for SGLT1 
upregulation in the heart; there is a 31% increase in SGLT1 
expression seen in obese HF patients without T2DM [75]. 
Furthermore, preclinical data on empagliflozin shows its 
effects on myocyte  Ca2+ and  Na+ is independent of extra-
cellular glucose levels and SGLT2 activity [85]. These find-
ings could possibly explain the equal benefit of dapagliflo-
zin in patients with or without T2DM in the DAPA-HF and 
EMPEROR-Reduced trials. Nevertheless, the only way to 
truly determine the effect of SGLT2-inhibiton on myocardial 
ionic homeostasis is by performing a dedicated clinical trial.
Powering the heart
The healthy heart utilises a variety of fuels to power its 
function. Under normal conditions, mitochondrial oxi-
dative phosphorylation accounts for 95% of myocardial 
energy demands, whilst only 5% is met by glycolysis and 
TCA cycle. Between 70%—90% of the ATP generated by 
the heart is derived from free fatty acids (FFA) and the 
remainder from glucose and other substrates such as ketones, 
branch chain amino acids and lactate [86]. The heart can 
rapidly alter its fuel mix between these substrates depending 
upon the workload, perfusion and substrate bioavailability 
[87]. There are, however, important differences between 
these fuels; FFA requires more oxygen per ATP molecule 
produced compared to the more oxygen efficient glucose. 
However, each molecule of the energy dense FFA produces 
more ATP than that of glucose. Interestingly, ketones are 
more efficient than both, producing more energy with less 
oxygen compared to glucose and FFA respectively – leading 
to it being dubbed as a ‘super fuel’ [88].
FFAs are the primary energy source for the heart  under 
most conditions, although its proportion of the overall fuel 
mix changes situationally. For example in the post prandial 
state, with higher circulating glucose and insulin, there is 
increased glucose uptake through myocardial GLUT pro-
teins [86]. Following exercise when levels are raised, more 
lactate is used for energy production. Similarly, when ketone 
levels are raised it becomes the preferred fuel; and the heart 
has been shown to be able to oxidise more ketones per unit 
of mass than any other organ [89]. In contrast, during high 
intensity exercise (physiological hypoxemia) or ischae-
mia (pathological) there is a shift toward the more oxygen-
efficient glucose and glycolytic ATP production [88].
This shift in metabolism to favour glucose over FFA is a 
rapid response mechanism to acute changes, however, just 
like neurohormonal activation in the context of ventricular 
loading, if left unchecked it can result in ‘metabolic remod-
elling’ leading to cardiomyocyte dysfunction. Indeed, it is 
the most consistent metabolic change seen in animal and 
clinical studies of HF. A chronic overreliance on glucose 
results in suppression of genes related to FFA beta-oxidation 
pathways including their upstream regulators such as PPAR-
alpha [90]. Downregulation of FFA oxidation capacity 
causes intracytoplasmic FFA accumulation, resulting in car-
diac steatosis and lipotoxicity from reactive oxygen species 
[91]. Additionally, there will also be a large energy deficit 
due to the inability of glucose to produce nearly as much 
ATP as FFA oxidation. Together, this metabolic remodelling 
results in increased cellular toxicity and an energy deficit, 
culminating in cardiomyocyte dysfunction [90] (Fig. 4).
On the other hand, insulin resistance and increased pro-
inflammatory cytokinesis (TNF and IL-6) which are hall-
marks of T2DM, also induce lipolysis thereby increasing 
FFA delivery to the cardiomyocyte and worsening lipo-
toxicity [92]. As a further complication, insulin resistance 
reduces glucose delivery into the cardiomyocyte from insu-
lin-sensitive GLUT4 (predominant route of glucose entry 
into cardiomyocyte) and GLUT8, forcing the heart to rely 
on the lower capacity (and insulin-independent) GLUT1 and 
SGLT1 routes. This exacerbates the energy deficit already 
present from lipotoxicity, thereby accelerating cardiomyo-
cyte dysfunction [90, 93].
Given the effects of the various fuel substrates on cardiac 
efficiency and potentially even cellular dysfunction, optimiz-
ing myocardial energetics could be a key therapeutic tar-
get for patients with HF and T2DM. SGLT2-inhibitors are 
uniquely poised to fill this area of need as they have consist-
ently shown to increase plasma ketone levels by increased 
hepatic synthesis from lipolysis and reduced renal loss [94]. 
(Fig. 2) Indeed, a recent porcine model of post infarct HF 
found metabolic remodelling with reduced FFA metabolism 
and anaerobic glycolysis resulted in a significant energy 
deficit. However, treatment with empagliflozin was able to 
switch myocardial metabolism away from anaerobic glyco-
lysis toward utilisation of ketones, FFA and branch chain 
amino acids. The improved energetics resulted in higher 
myocardial ATP content and reduced adverse LV remod-
elling, enhanced LV function and reduced neurohormonal 
activation at 2 months post infarct [89]. Clinically, Nielsen 
and colleagues showed that an infusion of ketones bodies 
in patients with HF resulted in increased cardiac output and 
improved EF with an associated increase in heart rate and 
myocardial oxygen consumption. This was a small, proof of 
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concept trial in HF patients without T2DM where measure-
ments were taken acutely following ketone infusion, admin-
istered in low dose insulinemic euglycaemic clamp condi-
tions, acheiving fairly high levels of ketonemia [95]. It is yet 
unclear what the effects of a more modest, chronic ketone-
mia, as seen in SGLT2-inhibition, will be. There are ongoing 
efforts to determine the clinical effect of SGLT2-inhibition 
on myocardial energetics in the context of HF [96]. These 
studies will help determine if the future of managing HF 
will include metabolic modulation to improve myocardial 
energetics just as neurohormonal modulation to improve 
ventricular loading forms the backbone of HF therapeutics 
today.
SGLT2‑inhibitor induced erythropoiesis
SGLT2-inhibitors increase haemoglobin and haematocrit 
levels. Initially these observations were attributed solely 
to haemoconcentration from its diuretic effect [97]. We 
now know that although there is an initial rise in urinary 
volume, this plateaus after a few weeks but haematocrit 
continues to rise well beyond that, suggesting a different 
mechanism driving this effect [98]. There is strong evi-
dence demonstrating SGLT2-inhibition inducing eryth-
ropoiesis; a 12-week study reported increased haemato-
crit, haemoglobin, reticulocyte count and erythropoietin 
(EPO) with dapagliflozin [99], with similar results in a 
trial using empagliflozin in patients with T2DM and ish-
caemic heart disease [100].
The mechanism behind these observations have yet to be 
elucidated, however there are a few hypotheses. EPO is syn-
thesized in the renal cortex by EPO-producing fibroblasts. 
Patients with T2DM have increased filtration of glucose 
resulting in upregulation of SGLT1 and SGLT2 in the PCT 
to increase glucose resorption capacity, however this is a net 
energy-consuming process. The resulting relative cortical 
hypoxia and increased oxidative stress from higher energy 
demands of these transporters in the renal cortex causes the 
cortical fibroblasts to undergo transformation into myofibro-
blasts which no longer produce EPO. SGLT2-inhibitors block 
these transporters, thereby reducing energy demands—the 
cortical injury is reduced, the transformation reverses and 
EPO production capacity is restored. Additionally, SGLT2-
inhibition increases sodium delivery to the distal portions of 
the nephron which causes upregulation of medullary sodium 
transporters in the loop of henle and terminal nephron result-
ing in relative medullary hypoxia, which stimulates eryth-
ropoiesis. It has also been suggested that increased plasma 
ketone levels, which are associated with SGLT2-inhibitor 
use, directly contribute to EPO synthesis [100, 101].
There is evidence that erythropoiesis-stimulating agents 
(in the non-HF population) have beneficial cardiac effects 
including increased survival following ischaemia–reperfu-
sion injury, reduced apoptosis, increased angiogenesis and 
improved myocardial contractility [102–104]. However, 
previous trials using various erythropoiesis-stimulating 
agents in patients with HF have been underwhelming and 
in the case of darbepoetin alfa, there was no effect on HF 
outcomes, but an increased risk of thromboembolic events 
[105]. Indeed, this was also an initial concern with SGLT2-
inhibitor therapy [106] but that has not been borne out with 
more recent trials and real-world data [18, 22, 23, 107]. In 
fact, a mediation analysis of the EMPA-REG OUTCOME 
showed changes in haemoglobin and haematocrit were 
responsible for approximately 50% of the risk reduction 
in CV death in that trial [108]. Perhaps SGLT2-inhibitors 
induce a more physiological effect, by restoring favourable 
renal physiology, which is salutary to the heart compared 
to exogenous stimulation of erythropoiesis by other agents.
Modulation of the sympathetic nervous system
The sympathetic nervous system is closely linked to the 
pathophysiology of HF and T2DM. Hypoperfusion from 
HF results in sympathetic activation, however persistently 
elevated sympathetic activity results in ventricular remod-
elling that perpetuates HF [109]. Similarly, insulin resist-
ance in T2DM results in hyperinsulinemia which increases 
sympathetic tone through effects on central nervous outflow, 
baroreceptor reflex sensitivity and alteration of noradrena-
line metabolism. However, persistently increased sympa-
thetic activity results in insulin resistance from chronic skel-
etal muscle beta-adrenergic receptor activation and muscle 
hypoperfusion from persistent alpha-adrenergic vasocon-
striction within skeletal muscles [110].
Interestingly, SGLT2-inhibitors have also shown poten-
tial in modulating sympathetic activity, thereby break-
ing the vicious cycle of chronic sympathetic activation in 
patients with T2DM and HF. Large clinical trials thus far 
have shown no reflex increase in heart rate following BP 
reduction from SGLT2-inhibition; a surrogate marker for 
sympathetic blockade. Mechanistic studies have supported 
these findings by demonstrating lower plasma metanephrines 
[89] and reduced noradrenaline and tyrosine hydroxylase 
(rate-limiting enzyme in catecholamine synthesis) activity 
in animal models [111]. Others have also noted that ketone 
bodies (which are increased with SGLT2-inhibitor therapy) 
Fig. 4  Schematic representation of myocardial energy consumption. 
Figure 3a: Myocardial energetics in healthy heart under resting con-
ditions. Figure 3b: Myocardial energetics as a consequence of heart 
failure and type 2 diabetes. Figure 3c: Changes in myocardial ener-
getics with the use of SGLT2-inhibitor therapy in patients with heart 
failure and type 2 diabetes Abbreviations: ATP-adenosine triphos-
phate; BCAA-branch chain amino acid; FFA-free fatty acid; HF-
heart failure; ROS-reactive oxygen species; SGLT2- sodium-glucose 
cotransporter subtype 2; T2DM- type 2 diabetes mellitus
◂
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attenuate sympathetic tone by suppressing G protein-cou-
pled receptor 41 (GPR41) which is widely distributed in 
sympathetic ganglia [112]. These effects may also be respon-
sible for lower sudden cardiac deaths in patients on SGLT2-
inhibiton due to lower arrhythmia potential.
SGLT2 inhibitors – a new paradigm
The pathophysiology of HF involves 2 overarching themes 
– abnormal loading conditions on the heart (the failing 
pump) and dysfunctional mechanics at the cellular level 
(the failing cardiomyocyte) [113]. Insofar as the treatment 
of chronic HF is concerned, the benefit derived from cur-
rent HF therapies are ‘mechanical’ due to favourable effects 
on ventricular loading. For the majority of patients, in spite 
of optimized loading conditions, HF disease progression 
continues unabated due to ongoing cellular dysfunction. 
We propose that SGLT2-inhibitors are uniquely poised to 
address this important but frequently overlooked and poorly 
understood aspect of HF.
Nevertheless, there may be a differential effect depending 
on where the patient is on the HF disease spectrum. In the 
early stages, with adequate cellular functional reserve, opti-
mizing the molecular milieu within the cardiomyocyte with 
SGLT2-inhibitor therapy (i.e. improved calcium handling, 
efficient myocardial energetics, optimized oxygen delivery 
etc.) along with modest improvements in ventricular load-
ing (i.e. diuresis and reduced BP) confers a large benefit. 
However, that benefit gradually wanes as cellular dysfunc-
tion, and indeed, cellular death occurs. In such advanced 
circumstances, improving haemodynamic loading becomes 
key, with the heavy lifting being done by neurohormonal 
modulators and SGLT2-inhibitors playing an important, 
but secondary role. If this hypothesis is true, then SGLT2-
inhibitors will very likely be the first therapeutic agent to be 
beneficial in patients with HFpEF where cardiomyocyte dys-
function predominates – we will have to wait and see if this 
is borne out in the large clinical trials currently underway.
Conclusions
Some have dubbed treating HF as the “last great battle in 
the war on cardiovascular disease” [113]. Despite great 
advances in treatment options, managing HF in the modern 
era remains an uphill battle. SGLT2-inhibitors have demon-
strated great promise in the prevention and treatment of HF 
and CKD. As more clinical data are collected, its therapeutic 
potential is being realised well beyond its initial intended 
use as a diabetes drug. With a clearer understanding of these 
molecular mechanisms, we will be able to fully harness its 
true potential and perhaps even pave the way for a new era of 
molecular therapeutic agents in this fight against HF.
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